Knight Therapeutics Inc. Celebrates its First Decade of Success
February 28 2024 - 7:30AM
Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American
(ex-USA) specialty pharmaceutical company, announced today that it
is marking its 10-year anniversary, and celebrating a decade of
expansion and growth.
Since its inception on February 28, 2014, Knight
has delivered significant milestones and made progress on its
strategy of building a profitable pan-American (ex US) company
commercializing both innovative and branded generic pharmaceuticals
products and talented people.
Key Accomplishments:
- Built a Unique Platform in
Canada & Latin AmericaKnight has invested over $925
million to build its unique pan-American (ex US) platform of
innovative and branded generic pharmaceuticals. Today, Knight has
over 700 talented employees operating in Canada and 10 Latin
American markets. Knight is a fully integrated company with
capabilities spanning regulatory, quality, pharmacovigilance,
compliance, medical, market access, marketing, sales and supply
chain in all 11 countries, as well as branded generic development
and manufacturing capabilities in Argentina.
- Delivered Profitable
GrowthKnight has delivered consecutive years of record
revenues since 2014 and EBITDA since 2019. As at Q3-23, Knight
delivered trailing twelve months revenue of over $335 million and
adjusted EBITDA of over $61 million representing a respective CAGR
of 22.7% and 20.7% since the 100% acquisition of Grupo Biotoscana
in 2020.
- Partner of
ChoiceKnight has a platform which offers a one-stop-shop
solution for biotech and pharmaceutical companies seeking a
commercialization partner in our 11 territories. Since the
completion of the acquisition of Biotoscana, Knight has entered
into 11 new partnerships for 13 innovative and branded generic
products.
- Strong Pipeline Expected to
Deliver Over $120 Million in Peak RevenuesKnight has
assembled a strong pipeline across our territories of 17 products
which include products in early launch or in various stages of
development. The products are projected to be launched by 2028 and
Knight has advanced the pipeline with the submission of 8 of these
products for regulatory approval in at least one country.
When reflecting on Knight’s accomplishments
since founding, Jonathan Ross Goodman, Knight’s Executive Chairman,
said “We are doing exactly what we said we would do in 2014 – we
built a fabulous pharmaceutical company with talented motivated
Knights delivering pharmaceuticals to Canadians and Latin
Americans. During these 10 years, we have generated $379 million1
and we will continue to strengthen on our platform and bring
shareholder value.”
“I am incredibly proud of what we have
accomplished to date and I am excited about the future achievements
that we will deliver to all of our stakeholders. None of this would
be possible without the fantastic team that we have in place across
all our countries. Their unwavering commitment and dedication to
serving patients have been instrumental in shaping Knight as the
partner of choice for Canada and Latin America,” said Samira
Sakhia, President and Chief Executive Officer.
About Knight Therapeutics
Inc.
Knight Therapeutics Inc., headquartered in
Montreal, Canada, is a specialty pharmaceutical company focused on
acquiring or in-licensing and commercializing pharmaceutical
products for Canada and Latin America. Knight’s Latin American
subsidiaries operate under United Medical, Biotoscana Farma and
Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX
under the symbol GUD. For more information about Knight
Therapeutics Inc., please visit the company's web site
at www.knighttx.com or www.sedarplus.ca.
Forward-Looking
Statements
This document contains forward-looking
statements for Knight Therapeutics Inc. and its subsidiaries. These
forward-looking statements, by their nature, necessarily involve
risks and uncertainties that could cause actual results to differ
materially from those contemplated by the forward-looking
statements. Knight Therapeutics Inc. considers the assumptions on
which these forward-looking statements are based to be reasonable
at the time they were prepared but cautions the reader that these
assumptions regarding future events, many of which are beyond the
control of Knight Therapeutics Inc. and its subsidiaries, may
ultimately prove to be incorrect. Factors and risks which could
cause actual results to differ materially from current expectations
are discussed in Knight Therapeutics Inc.'s Annual Report and in
Knight Therapeutics Inc.'s Annual Information Form for the year
ended December 31, 2022, as filed on www.sedarplus.ca. Knight
Therapeutics Inc. disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of
new information or future events, except as required by law.
CONTACT INFORMATION FOR
KNIGHT:
Investor Contact: |
|
Knight Therapeutics Inc. |
|
Samira Sakhia |
Arvind Utchanah |
President & Chief Executive Officer |
Chief Financial Officer |
T: 514.484.4483 |
T. +598.2626.2344 |
F: 514.481.4116 |
|
Email: IR@knighttx.com |
Email: IR@knighttx.com |
Website: www.knighttx.com |
Website: www.knighttx.com |
1 Represents the sum of net income from 2014 to 2018 and
adjusted EBITDA from 2019 to Q3-23 YTD
Knight Therapeutics (TSX:GUD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Knight Therapeutics (TSX:GUD)
Historical Stock Chart
From Apr 2023 to Apr 2024